Related Experiment Video
Updated: May 5, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Will antiretroviral therapy reduce HIV-related liver risk?
Joanna Allen1, Colette Smith, Sanjay Bhagani
1aDepartment of Infectious Diseases and HIV Medicine bResearch Department of Infection and Population Health, UCL, Royal Free Campus, London, United Kingdom.
Purpose Of Review:
With the introduction of combined antiretroviral therapy (cART) and consequent reduction in the incidence of AIDS-related mortality, there has been a relative increase in the importance of non-AIDS-related conditions such as liver disease. This article reviews the positive and potential negative impact of cART on liver-related morbidity and mortality.
Recent Findings:
Though non-AIDS-related mortality, and particular, liver disease now accounts for a larger proportion of deaths in HIV-positive individuals than we have previously seen, liver-related mortality is decreasing. This is likely to be as a result of both the use of cART and improved patient management. Most liver-related mortality is related with viral hepatitis, the outcomes of which are improved with cART. Serious hepatotoxicity and death from cART is rare and mainly attributable to older antiretroviral drugs.
Summary:
This review shows that outcomes are improving, but more work is required to improve liver-related morbidity and mortality further and determine any other longer-term positive and negative effects of cART.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

